{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:19:22Z","timestamp":1721089162400},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,14]]},"DOI":"10.7759\/cureus.64545","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T06:43:00Z","timestamp":1721025780000},"source":"Crossref","is-referenced-by-count":0,"title":["An Unusual Occurrence of Tamoxifen-Induced Maculopathy in a Young Woman With Hormone Receptor-Positive Post-mastectomy Breast Carcinoma"],"prefix":"10.7759","author":[{"given":"Deeksha","family":"Jawale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Bhoj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amitabh","family":"Pandagle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmita","family":"Kulshrestha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00620","article-title":"Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: a case-study in pharmaceutical innovation","volume":"8","author":"Quirke VM","year":"2017","unstructured":"Quirke VM. Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: a case-study in pharmaceutical innovation. Front Pharmacol. 2017, 8:620. 10.3389\/fphar.2017.00620","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198902233200802","article-title":"A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors","volume":"320","author":"Fisher B","year":"1989","unstructured":"Fisher B, Costantino J, Redmond C, et al.. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989, 320:479-84. 10.1056\/NEJM198902233200802","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S43763","article-title":"Tamoxifen for women at high risk of breast cancer","volume":"6","author":"Nazarali SA","year":"2014","unstructured":"Nazarali SA, Narod SA. Tamoxifen for women at high risk of breast cancer. Breast Cancer (Dove Med Press). 2014, 6:29-36. 10.2147\/BCTT.S43763","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"ref4","article-title":"Tamoxifen","author":"Farrar MC","year":"2023","unstructured":"Farrar MC, Jacobs TF. Tamoxifen. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-317510","article-title":"Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors","volume":"107","author":"Matthews AA","year":"2021","unstructured":"Matthews AA, Peacock Hinton S, Stanway S, Lyon AR, Smeeth L, Lund JL, Bhaskaran K. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. Heart. 2021, 107:1327-35. 10.1136\/heartjnl-2020-317510","journal-title":"Heart"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000140491.54664.50","article-title":"Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis","volume":"63","author":"Bushnell CD","year":"2004","unstructured":"Bushnell CD, Goldstein LB. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology. 2004, 63:1230-3. 10.1212\/01.wnl.0000140491.54664.50","journal-title":"Neurology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer","volume":"31","author":"Gray RG","year":"2013","unstructured":"Gray RG, Rea D, Handley K, et al.. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013, 31:5. 10.1200\/jco.2013.31.18_suppl.5","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji057","article-title":"Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study","volume":"97","author":"Swerdlow AJ","year":"2005","unstructured":"Swerdlow AJ, Jones ME. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst. 2005, 97:375-84. 10.1093\/jnci\/dji057","journal-title":"J Natl Cancer Inst"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1023\/a:1006342300291","article-title":"Eye problems in breast cancer patients treated with tamoxifen","volume":"60","author":"Paganini-Hill A","year":"2000","unstructured":"Paganini-Hill A, Clark LJ. Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000, 60:167-72. 10.1023\/a:1006342300291","journal-title":"Breast Cancer Res Treat"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1999.217","article-title":"Ocular toxicity in low-dose tamoxifen: a prospective study","volume":"13 (Pt 6)","author":"Noureddin BN","year":"1999","unstructured":"Noureddin BN, Seoud M, Bashshur Z, Salem Z, Shamseddin A, Khalil A. Ocular toxicity in low-dose tamoxifen: a prospective study. Eye (Lond). 1999, 13 (Pt 6):729-33. 10.1038\/eye.1999.217","journal-title":"Eye (Lond)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.10.038","article-title":"Prevalence and risk factors of tamoxifen retinopathy","volume":"127","author":"Kim HA","year":"2020","unstructured":"Kim HA, Lee S, Eah KS, Yoon YH. Prevalence and risk factors of tamoxifen retinopathy. Ophthalmology. 2020, 127:555-7. 10.1016\/j.ophtha.2019.10.038","journal-title":"Ophthalmology"},{"key":"ref12","article-title":"Tamoxifen retinopathy","volume":"62","author":"Kaiser-Kupfer MI","year":"1978","unstructured":"Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep. 1978, 62:315-20.","journal-title":"Cancer Treat Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3109\/14767058.2015.1120717","article-title":"Fertility treatments and the risk for ophthalmic complications: a cohort study with 25-year follow-up","volume":"29","author":"Ratson R","year":"2016","unstructured":"Ratson R, Sheiner E, Davidson E, Sergienko R, Beharier O, Kessous R. Fertility treatments and the risk for ophthalmic complications: a cohort study with 25-year follow-up. J Matern Fetal Neonatal Med. 2016, 29:3094-7. 10.3109\/14767058.2015.1120717","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100985","article-title":"Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns","volume":"38","author":"Lima SM","year":"2021","unstructured":"Lima SM, Kehm RD, Terry MB. Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. EClinicalMedicine. 2021, 38:100985. 10.1016\/j.eclinm.2021.100985","journal-title":"EClinicalMedicine"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2023.07.003","article-title":"Tamoxifen retinopathy: a comprehensive review","volume":"69","author":"Tenney S","year":"2024","unstructured":"Tenney S, Oboh-Weilke A, Wagner D, Chen MY. Tamoxifen retinopathy: a comprehensive review. Surv Ophthalmol. 2024, 69:42-50. 10.1016\/j.survophthal.2023.07.003","journal-title":"Surv Ophthalmol"},{"key":"ref16","unstructured":"Maculopathy. causes, symptoms, types and treatment. (2022). Accessed: 14 June 2024: https:\/\/www.allaboutvision.com\/conditions\/macula\/maculopathy\/."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2021.01.003","article-title":"Age-related macular degeneration","volume":"105","author":"Thomas CJ","year":"2021","unstructured":"Thomas CJ, Mirza RG, Gill MK. Age-related macular degeneration. Med Clin North Am. 2021, 105:473-91. 10.1016\/j.mcna.2021.01.003","journal-title":"Med Clin North Am"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v6.i3.489","article-title":"Diabetic retinopathy - ocular complications of diabetes mellitus","volume":"6","author":"Nentwich MM","year":"2015","unstructured":"Nentwich MM, Ulbig MW. Diabetic retinopathy - ocular complications of diabetes mellitus. World J Diabetes. 2015, 6:489-99. 10.4239\/wjd.v6.i3.489","journal-title":"World J Diabetes"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/267905-an-unusual-occurrence-of-tamoxifen-induced-maculopathy-in-a-young-woman-with-hormone-receptor-positive-post-mastectomy-breast-carcinoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T06:43:04Z","timestamp":1721025784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/267905-an-unusual-occurrence-of-tamoxifen-induced-maculopathy-in-a-young-woman-with-hormone-receptor-positive-post-mastectomy-breast-carcinoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,14]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.64545","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,14]]}}}